Pathologic and immunohistochemical findings in hypothalamic and mesencephalic regions in the Pahenu2 mouse model for phenylketonuria

Pediatric Research

Volumn 58, Issue 2, 2005, Pages 283-287

  Embury, Jennifer E ^a   Reep, Roger R ^b   Laipis, Philip J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b University of Florida   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; CD11B ANTIGEN; DOPAMINE; ETHYLNITROSOUREA; INDUCIBLE NITRIC OXIDE SYNTHASE; NEUROTRANSMITTER; PARVOVIRUS VECTOR; PHENYLALANINE; TRYPTOPHAN; TYROSINE;

ADOLESCENT; AGED; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; GENE THERAPY; HISTOPATHOLOGY; HYPERPHENYLALANINEMIA; HYPOPIGMENTATION; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MESENCEPHALON; MOTOR DYSFUNCTION; MOUSE; MOUSE STRAIN; MUTAGENESIS; NEUROPATHOLOGY; NONHUMAN; PAH ENU2 MOUSE; PHENYLKETONURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, CD11B; CATECHOLAMINES; DISEASE MODELS, ANIMAL; DOPAMINE; FEMALE; GENE TRANSFER TECHNIQUES; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MESENCEPHALON; MICE; MICE, MUTANT STRAINS; NEURONS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PHENYLKETONURIAS; SUBSTANTIA NIGRA; TIME FACTORS; TRYPTOPHAN; TYROSINE;

EID: 23244433161     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/01.PDR.0000170000.78670.44     Document Type: Article

References (25)

1. Scriver CR, Kaufman S 2001 Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The Metabolic and Molecular Bases of Inherited Disease, 8th Ed. McGraw-Hill, New York, pp 1665-1725
2. Blau N, Thony B, Cotton RGH, Hyland K 2001 Disorders of tetrahydrobiopterin and related biogenic amines. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The Metabolic and Molecular Bases of Inherited Disease, 8th Ed. McGraw-Hill, New York, pp 1726-1776
3. Pardridge WM 1998 Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochem Res 23:635-644
4. Kaufman S 1999 A model of human phenylalanine metabolism in normal subjects and phenylketonuric patients. Proc Natl Acad Sci USA 96:3160-3164
5. hph-5: a mouse mutant deficient in phenylalanine hydroxylase. Proc Natl Acad Sci USA 87:1965-1967
6. Shedlovsky A, McDonald JD, Symula D, Dove WF 1993 Mouse models of human phenylketonuria. Genetics 134:1205-1210
7. Cabib S, Pascucci T, Ventura R, Romano V, Puglisi-Allegra S 2003 The behavioral profile of severe mental retardation in a genetic mouse model of phenylketonuria. Behav Genet 33:301-310
8. Puglisi-Allegra S, Cabib S, Pascucci T, Ventura R, Cali F, Romano V 2000 Dramatic brain aminergic deficit in a genetic mouse model of phenylketonuria. Neuroreport 11:1361-1364
9. Joseph B, Dyer CA 2003 Relationship between myelin production and dopamine synthesis in the PKU mouse brain. J Neurochem 86:615-626
10. McDonald JD, Charlton CK 1997 Characterization of mutations at the mouse phenylalanine hydroxylase locus. Genomics 39:402-405
11. Paxinos G, Franklin KB 1997 The Mouse Brain in Stereotaxic Coordinates. Academic Press, London
12. Dyer CA, Kendler A, Philibotte T, Gardiner P, Cruz J, Levy HL 1996 Evidence for central nervous system glial cell plasticity in phenylketonuria. J Neuropathol Exp Neurol 55:795-814
13. Streit WJ 2002 Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 40:133-139
14. West AR, Galloway MP, Grace A 2002 Regulation of striatal dopamine neurotransmission by nitric oxide: effector pathways and signaling mechanisms. Synapse 44:227-245
15. Guevara-Guzman R, Emson PC, Kendrick KM 1994 Modulation of in vivo striatal transmitter release by nitric oxide and cyclic-GMP. J Neurochem 62:807-810
16. Buyukuysal L 1997 Effect of nitric oxide donors on endogenous dopamine release from striatal slices. 1. Requirement of antioxidants in the medium. Fundam Clin Pharmacol 11:519-527
17. Trabace L, Kendrick KM 2000 Nitric oxide can differentially modulate striatal neurotransmitter concentrations via soluble guanylate cyclase and peroxynitrite formation. J Neurochem 75:1664-1674
18. Ercal N, Aykin-Burns N, Gurer-Orhan H, McDonald JD 2002 Oxidative stress in a phenylketonuria animal model. Free Radic Biol Med 32:906-911
19. Colomé C, Artuch R, Vilaseca MA, Sierra C, Brandi N, Lambruschini N, Cambra FJ, Campistol J 2003 Lipophilic antioxidants in patients with phenylketonuria. Am J Clin Nutr 77:185-188
20. Kienzle Hagen ME, Pederzolli CD, Sgaravatti AM, Bridi R, Wajner M, Wannmacher C, Wyse AT, Dutra-Filho CS 2002 Experimental hyperphenylalaninemia provokes oxidative stress in rat brain. Biochim Biophys Acta 1586:344-352
21. Halliwell B, Gutteridge J 1989 Free Radicals in Biology and Medicine. Clarendon Press, Oxford
22. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedboski S 1999 Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Nat Med 5:1403-1409
23. Kornguth S, Anderson M, Markley JL, Shedlovsky A 1994 Near-microscopic magnetic resonance imaging of the brains of phenylalanine hydroxylase deficient mice, normal littermates, and of normal BALB/c mice at 9.4 Tesla. Neuroimage 1:220-229
24. Pakkenberg B, Moller A, Gundersen HJ, Mouritzen A, Pakkenberg H 1991 The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 54:30-33
25. Kumar V, Cotran R, Robbins SL 2003 Robbins Basic Pathology, 7th Ed. WB Saunders, Philadelphia, p 844